EGFR and neoplasm: It is conceivable that more aggressive regimens, combining CT with anti-angiogenic agents or monoclonal antibodies targeting epidermal growth factor receptor (EGFR), could lead to higher rates of tumor regression, including in patients with poor responses to CRT [113,114].